Pfizer Rethinks German Investments Amidst Drug Price Policy Concerns
10 Articles
10 Articles
Pfizer Rethinks German Investments Amidst Drug Price Policy Concerns
Pfizer is reconsidering its investment plans in Germany due to proposed government policies aimed at lowering drug prices, CEO Albert Bourla informed Chancellor Friedrich Merz. The changes raise uncertainty in the pharmaceutical sector, prompting Pfizer and others to reassess their investment strategies.
The US pharmaceutical company Pfizer criticizes the federal government's health policy and therefore overthinks its investments in Germany.
After Eli Lilly and Boehringer Ingelheim, Pfizer is also thinking about his investments in Germany. A meeting with the Federal Chancellor in the autumn was cancelled by the head of the Group.
Large pharmaceutical companies say they may not be able to launch innovative medicines in Europe unless governments agree to pay more
Criticism of austerity requirements for the pharmaceutical sector is growing: after two major investments have been stopped in Germany, the US giant Pfizer is also putting plans to the test – and rejects the chancellor.
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
